PharmAthene, Inc.  

(Public, NYSEMKT:PIP)   Watch this stock  
Find more results for NYSEAMEX:PIP
1.44
-0.01 (-0.70%)
Apr 24 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 1.42 - 1.45
52 week 1.33 - 2.42
Open 1.43
Vol / Avg. 87,607.00/183,623.00
Mkt cap 77.11M
P/E     -
Div/yield     -
EPS -0.23
Shares 53.56M
Beta 1.20
Inst. own 37%
May 8, 2014
Q1 2014 PharmAthene, Inc. Earnings Release -Tentative Add to calendar
Mar 11, 2014
Q4 2013 PharmAthene, Inc. Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -121.09% -65.42%
Operating margin -138.69% -60.51%
EBITD margin - -59.49%
Return on average assets -94.01% -58.77%
Return on average equity -189.92% -123.29%
Employees 52 -
CDP Score - -

Address

Suite #450, One Park Place
ANNAPOLIS, MD 21401
United States - Map
+1-410-2692600 (Phone)
+1-410-2692601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

PharmAthene, Inc. is a biodefense company engaged in the development and commercialization of medical countermeasures against biological and chemical threats. As of December 31, 2011, the Company�s biodefense portfolio of product candidates included SparVax, a second generation recombinant protective antigen (rPA) anthrax vaccine; Valortim, a fully human monoclonal antibody for the prevention and treatment of anthrax infection, and rBChE (recombinant butyrylcholinesterase) bioscavanger, a medical countermeasure for nerve agent poisoning by organophosphorous compounds, including nerve gases and pesticides.

Officers and directors

Mitchel B. Sayare Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Eric I. Richman President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Linda L. Chang Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Francesca M. Cook Senior Vice President - Policy and Government Affairs
Age: 48
Bio & Compensation  - Reuters
Wayne Morges Ph.D. Senior Vice President - Regulatory Affairs and Quality
Age: 66
Bio & Compensation  - Reuters
Elliott Y. Elliott Ph.D. Acting Chief Scientific Officer
Age: 77
Bio & Compensation  - Reuters
John M. Gill Independent Director
Age: 61
Bio & Compensation  - Reuters
Brian A. Markison Independent Director
Age: 54
Bio & Compensation  - Reuters
Joel W. McCleary Independent Director
Age: 64
Bio & Compensation  - Reuters
Jeffrey W. Runge M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters